Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms


Por: Temkin, E, Torre-Cisneros, J, Beovic, B, Benito, N, Giannella, M, Gilarranz, R, Jeremiah, C, Loeches, B, Machuca, I, Jimenez-Martin, MJ, Martinez, JA, Mora-Rillo, M, Navas, E, Osthoff, M, Pozo, JC, Ramos, JCR, Rodriguez, M, Sanchez-Garcia, M, Viale, P, Wolff, M, Carmeli, Y

Publicada: 1 feb 2017
Resumen:
Ceftazidime-avibactam (CAZ-AVI) is a recently approved beta-lactam-beta-lactamase inhibitor combination with the potential to treat serious infections caused by carbapenem-resistant organisms. Few patients with such infections were included in the CAZ-AVI clinical trials, and clinical experience is lacking. We present a case series of patients with infections caused by carbapenem-resistant Enterobacteriaceae (CRE) or Pseudomonas aeruginosa (CRPa) who were treated with CAZ-AVI salvage therapy on a compassionate-use basis. Physicians who had prescribed CAZ-AVI completed a case report form. We used descriptive statistics to summarize patient characteristics and treatment outcomes. We used the Wilcoxon rank sum test and Fisher's exact test to compare patients by treatment outcome. The sample included 36 patients infected with CRE and two with CRPa. The most common infections were intra-abdominal. Physicians categorized 60.5% of patients as having life-threatening infections. All but two patients received other antibiotics before CAZ-AVI, for a median of 13 days. The median duration of CAZ-AVI treatment was 16 days. Twenty-five patients (65.8%) concurrently received other antibiotics to which their pathogen was nonresistant in vitro. Twenty-eight patients (73.7%, 95% confidence interval [CI], 56.9 to 86.6%) experienced clinical and/or microbiological cure. Five patients (20.8%) with documented microbiological cure died, whereas 10 patients (71.4%) with no documented microbiological cure died (P = 0.01). In three-quarters of cases, CAZ-AVI (alone or combined with other antibiotics) cured infections caused by carbapenem-resistant organisms, 95% of which had failed previous therapy. Microbiological cure was associated with improved survival. CAZ-AVI shows promising clinical results for infections for which treatment options are limited.

Filiaciones:
Temkin, E:
 Tel Aviv Sourasky Med Ctr, Dept Epidemiol & Prevent Med, Tel Aviv, Israel

Torre-Cisneros, J:
 Hosp Univ Reina Sofia, Dept Infect Dis, Cordoba, Spain

 Univ Cordoba, Inst Maimonides Invest Biomed, Cordoba, Spain

Beovic, B:
 Univ Med Ctr Ljubljana, Dept Infect Dis, Ljubljana, Slovenia

Benito, N:
 Hosp Santa Creu & Sant Pau, Dept Med, Infect Dis Unit, Barcelona, Spain

 Univ Autonoma Barcelona, Inst Invest Biomed St Pau, Barcelona, Spain

Giannella, M:
 Univ Bologna, S Orsola Malpighi Hosp, Dept Med & Surg Sci, Infect Dis Unit, Bologna, Italy

Gilarranz, R:
 Hosp Univ Gran Canaria Doctor Negrin, Dept Clin Microbiol, Las Palmas Gran Canaria, Spain

Jeremiah, C:
 St Vincents Hosp, Dept Infect Dis, Melbourne, Vic, Australia

Loeches, B:
 Hosp Univ La Paz IdiPAZ, Infect Dis Unit, Madrid, Spain

Machuca, I:
 Hosp Univ Reina Sofia, Dept Infect Dis, Cordoba, Spain

 Univ Cordoba, Inst Maimonides Invest Biomed, Cordoba, Spain

Jimenez-Martin, MJ:
 Hosp Clin San Carlos, Crit Care Dept, Madrid, Spain

Martinez, JA:
 Univ Barcelona, IDIBAPS, Hosp Clin, Dept Infect Dis, Barcelona, Spain

Mora-Rillo, M:
 Hosp Univ La Paz IdiPAZ, Infect Dis Unit, Madrid, Spain

Navas, E:
 Hosp Ramon & Cajal, Dept Infect Dis, Madrid, Spain

Osthoff, M:
 Univ Basel Hosp, Div Infect Dis & Hosp Epidemiol, Basel, Switzerland

Pozo, JC:
 Hosp Univ Reina Sofia, Dept Crit Care Med, Cordoba, Spain

Ramos, JCR:
 Hosp Univ La Paz IdiPAZ, Infect Dis Unit, Madrid, Spain

Rodriguez, M:
 Hosp Univ Reina Sofia, Dept Crit Care Med, Cordoba, Spain

Sanchez-Garcia, M:
 Hosp Clin San Carlos, Crit Care Dept, Madrid, Spain

Viale, P:
 Alma Mater Studiorum Univ Bologna, Dept Med Surg Sci, Bologna, Italy

Wolff, M:
 Ctr Hosp Univ Bichat Claude Bernard, AP HP, Paris, France

 Univ Paris Diderot, Paris, France

Carmeli, Y:
 Tel Aviv Sourasky Med Ctr, Dept Epidemiol & Prevent Med, Tel Aviv, Israel

 Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
ISSN: 00664804
Editorial
AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 61 Número: 2
Páginas:
WOS Id: 000394102500050
ID de PubMed: 27895014
imagen Green Published, Bronze

MÉTRICAS